Cancers (Oct 2023)

Epigenetic Profiling of <i>PTPN11</i> Mutant JMML Hematopoietic Stem and Progenitor Cells Reveals an Aberrant Histone Landscape

  • Roshani Sinha,
  • Mai Dvorak,
  • Ananthakrishnan Ganesan,
  • Larry Kalesinskas,
  • Charlotte M. Niemeyer,
  • Christian Flotho,
  • Kathleen M. Sakamoto,
  • Norman Lacayo,
  • Rachana Vinay Patil,
  • Rhonda Perriman,
  • Alma-Martina Cepika,
  • Yunying Lucy Liu,
  • Alex Kuo,
  • Paul J. Utz,
  • Purvesh Khatri,
  • Alice Bertaina

DOI
https://doi.org/10.3390/cancers15215204
Journal volume & issue
Vol. 15, no. 21
p. 5204

Abstract

Read online

Juvenile myelomonocytic leukemia (JMML) is a deadly pediatric leukemia driven by RAS pathway mutations, of which >35% are gain-of-function in PTPN11. Although DNA hypermethylation portends severe clinical phenotypes, the landscape of histone modifications and chromatin profiles in JMML patient cells have not been explored. Using global mass cytometry, Epigenetic Time of Flight (EpiTOF), we analyzed hematopoietic stem and progenitor cells (HSPCs) from five JMML patients with PTPN11 mutations. These data revealed statistically significant changes in histone methylation, phosphorylation, and acetylation marks that were unique to JMML HSPCs when compared with healthy controls. Consistent with these data, assay for transposase-accessible chromatin with sequencing (ATAC-seq) analysis revealed significant alterations in chromatin profiles at loci encoding post-translational modification enzymes, strongly suggesting their mis-regulated expression. Collectively, this study reveals histone modification pathways as an additional epigenetic abnormality in JMML patient HSPCs, thereby uncovering a new family of potential druggable targets for the treatment of JMML.

Keywords